 |
Coagulation Factor VIIa (Recombinant) |
|---|---|
| Trade Name | Novoseven |
| Orphan Indication | Bleeding in patients experiencing intracranial hemorrhage |
| USA Market Approval | USA |
| USA Designation Date | 2006-10-03 00:00:00 |
| Sponsor | Novo Nordisk, Inc.;P. O. Box 846;Plainsboro, New Jersey, 08536 |
